Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellectis (CLLS) Common Equity (2016 - 2025)

Cellectis has reported Common Equity over the past 12 years, most recently at $75.9 million for Q4 2025.

  • Quarterly results put Common Equity at $75.9 million for Q4 2025, down 42.07% from a year ago — trailing twelve months through Dec 2025 was $75.9 million (down 42.07% YoY), and the annual figure for FY2025 was $75.9 million, down 42.07%.
  • Common Equity for Q4 2025 was $75.9 million at Cellectis, down from $131.0 million in the prior quarter.
  • Over the last five years, Common Equity for CLLS hit a ceiling of $236.5 million in Q4 2021 and a floor of $75.9 million in Q4 2025.
  • Median Common Equity over the past 5 years was $96.6 million (2023), compared with a mean of $118.1 million.
  • Biggest five-year swings in Common Equity: crashed 46.74% in 2022 and later soared 54.71% in 2024.
  • Cellectis' Common Equity stood at $236.5 million in 2021, then plummeted by 46.74% to $125.9 million in 2022, then plummeted by 32.75% to $84.7 million in 2023, then soared by 54.71% to $131.0 million in 2024, then tumbled by 42.07% to $75.9 million in 2025.
  • The last three reported values for Common Equity were $75.9 million (Q4 2025), $131.0 million (Q4 2024), and $84.7 million (Q4 2023) per Business Quant data.